Maxine Gowen, Ph.D. has served as a member of our Board of Directors since February 2021, and as Chairwoman of the Board since September 2021. Dr. Gowen served as Chief Executive Officer of Tamuro Bio from July 2019 to December 2021. Dr. Gowen served as the founding President and Chief Executive Officer of Trevena, Inc. from 2007 to October 2018, and served as a member of Trevena’s Board of Directors from 2008 to 2021. Dr. Gowen previously held a variety of leadership roles at GlaxoSmithKline over a period of 15 years. She also currently serves on the boards of directors for Aceragen Inc., Merus N.V., and Aclaris Therapeutics, Inc., each a public biotechnology company, as well as one private company. Dr. Gowen previously served on the Board of Directors and executive committee of BIO, an industry association, from 2008 – 2022, the Board of Directors of Akebia Therapeutics, Inc from 2014 – 2021, the Board of Directors and executive committee of Trevena, Inc from 2008 – 2021, and the Board of Directors and executive committee of Life Sciences Pennsylvania, an industry association from 2016 - 2021. Dr. Gowen received a B.Sc. in biochemistry from the University of Bristol, U.K., a Ph.D. in cell biology from the University of Sheffield, U.K., and an M.B.A. from the Wharton School of the University of Pennsylvania.